Related Experiment Video
Updated: Jul 5, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Established and emerging biomarkers of immunotherapy in renal cell carcinoma
Yash Jani1, Caroline S Jansen2,3, Margo B Gerke2
1Mercer University, Macon, GA 31207, USA.
Abstract:
Immunotherapies, such as immune checkpoint inhibitors, have heralded impressive progress for patient care in renal cell carcinoma (RCC). Despite this success, some patients' disease fails to respond, and other patients experience significant side effects. Thus, development of biomarkers is needed to ensure that patients can be selected to maximize benefit from immunotherapies. Improving clinicians' ability to predict which patients will respond to immunotherapy and which are most at risk of adverse events - namely through clinical biomarkers - is indispensable for patient safety and therapeutic efficacy. Accordingly, an evolving suite of therapeutic biomarkers continues to be investigated. This review discusses biomarkers for immunotherapy in RCC, highlighting current practices and emerging innovations, aiming to contribute to improved outcomes for patients with RCC.
Insights
Biomarkers are crucial for predicting patient response to immunotherapy in renal cell carcinoma (RCC). This helps maximize treatment benefits and minimize adverse events for better patient outcomes.
Area of Science:
- Oncology
- Immunology
Background:
- Immunotherapies, including immune checkpoint inhibitors, show promise in renal cell carcinoma (RCC) treatment.
- However, variable patient response and side effects necessitate predictive biomarkers.
Purpose of the Study:
- To review current and emerging biomarkers for immunotherapy in RCC.
- To guide selection of patients likely to benefit from immunotherapy and identify those at risk of adverse events.
Main Methods:
- Literature review of current practices and emerging innovations in RCC immunotherapy biomarkers.
Main Results:
- Discusses the role of biomarkers in optimizing immunotherapy selection for RCC patients.
- Highlights the need for clinical biomarkers to improve patient safety and therapeutic efficacy.
Conclusions:
- Biomarker development is essential for personalized immunotherapy in RCC.
- Improved prediction of treatment response and adverse events will enhance patient outcomes.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
